We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

PTAB Denies Hedge Fund's Bid For Painkiller Patent Reviews

Law360, New York (March 10, 2016, 4:46 PM EST) -- The Patent Trial and Appeal Board on Thursday refused to review three Insys Pharma Inc. patents for the pain medication Subsys, ruling hedge fund manager Kyle Bass and his group failed to show the patents are likely invalid.

In separate decisions, the PTAB denied three petitions the Coalition for Affordable Drugs filed in August, in which it argued the patents were invalid because they were made obvious by a collection of earlier inventions and published writings. It also argued a handful of claims were anticipated....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.